Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Fate Therapeutics

13/08/2026 15:54

Fate Therapeutics Inc FATE.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -29 cents.  The mean expectation of twelve analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -29 cents to -23 cents per share.
Revenue rose 9.2% to $2.08 million from a year ago; analysts expected $1.37 million. 
Fate Therapeutics Inc's reported EPS for the quarter was a loss of 25 cents​.
The company reported a quarterly loss of $30.16 million.
Fate Therapeutics Inc shares had risen by 0.7% this quarter and gained 176.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Fate Therapeutics Inc is $6.50, about 58.2% above its last closing price of $2.72
This summary was machine generated from LSEG data August 13 at 02:54 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.27
-0.25
Beat
Mar. 31 2026 
-0.28
-0.26
Beat
Dec. 31 2025 
-0.27
-0.27
Met
Sep. 30 2025 
-0.29
-0.27
Beat